Governance Savara Inc.

SVRA

US8051111016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/06/2026 BST			5-day change	1st Jan Change
5.090 ^USD	+3.25%		-3.05%	-15.59%

06-08	Savara Inc. Announces CFO Changes	CI
06-08	Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026	CI

Executive Committee: Savara Inc.

Manager

Positions heldSince

Matthew Pauls

55 year

Chief Executive Officer

30/11/2020

Yasmine Wasfi

Chief Tech/Sci/R&D Officer

30/11/2023

Charles LaPree

General Counsel

31/07/2021

Kate McCabe

40 year

General Counsel

28/02/2018

Temre Johnson

Investor Relations Contact	31/10/2024
Public Communications Contact	31/10/2024

Robert Lutz

57 year

Chief Operating Officer

12/02/2023

David Lowrance

58 year

Chief Administrative Officer	12/12/2022
Director of Finance/CFO	31/10/2016
Corporate Secretary	30/06/2017

Composition of the Board of Directors: Savara Inc.

Director

CommitteesSince

Matthew Pauls

55 year

Audit Committee
Compensation Committee Chair

An van Es-Johansson

66 year

Audit Committee
Compensation Committee	02/12/2019
Governance Committee
Nominating Committee
Compensation Committee Chair
Governance Committee Chair

Nevan Elam

58 year

Governance Committee	26/04/2017
Nominating Committee	26/04/2017
Compensation Committee Chair	26/04/2017

Joseph McCracken

72 year

Compensation Committee	26/04/2017
Governance Committee Chair	26/04/2017
Nominating Committee Chair	26/04/2017

Richard Hawkins

77 year

Audit Committee

26/04/2017

David Ramsay

61 year

Audit Committee Chair

26/04/2017

Latest Appointments: Savara Inc.

06-08	Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026	CI
17/10/25	Savara Inc. Announces Executive Changes	CI
02/10/24	Savara Appoints Braden Parker as Chief Commercial Officer	CI
12/04/24	Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection	CI
14/02/23	Savara Appoints Rob Lutz Chief Operating Officer	MT
14/02/23	Savara Inc. Announces New Leadership Appointments	CI
02/01/23	Indian food delivery firm Zomato's co-founder Patidar resigns	RE

More news

Former Officers and Directors: Savara Inc.

Insider

Positions held

SinceUntil

Raymond Pratt

Chief Tech/Sci/R&D Officer

30/09/2023

16/10/2025

Ricky Sun

Director/Board Member	23/12/2019	05/06/2024
Independent Dir/Board Member	23/12/2019	05/06/2024

Badrul Chowdhury

Chief Tech/Sci/R&D Officer

17/11/2019

08/09/2022

Peter M. Clarke

Corporate Officer/Principal

31/08/2021

Dhaval Desai

Chief Tech/Sci/R&D Officer

30/04/2021

Cecilia Ganslandt

Chief Tech/Sci/R&D Officer	30/06/2016	28/02/2021
Corporate Officer/Principal	30/06/2016	-

Michael Ciesla

Corporate Officer/Principal

31/01/2021

Peter L. Ginsberg

Corporate Officer/Principal

03/01/2018

31/10/2020

Taneli Jouhikainen

Chief Operating Officer	26/04/2017	26/05/2020
President	26/04/2017	10/09/2020

Robert Norman Neville

Chief Executive Officer	26/04/2017	10/09/2020
Chairman	26/04/2017	10/09/2020

Yuri Pikover

Director/Board Member	31/07/2013	30/11/2019
Independent Dir/Board Member	31/07/2013	30/11/2019

John Lord

Chief Tech/Sci/R&D Officer

30/04/2019

Howard C. Dittrich

Director/Board Member

26/04/2017

Edwin L. Parsley

Chief Tech/Sci/R&D Officer

26/04/2017

Brian Culley

Director/Board Member	-	26/04/2017
Chief Executive Officer	-	26/04/2017

Shana C. Hood

General Counsel	-	26/04/2017
Corporate Secretary	-	26/04/2017

Peter Greenleaf

Director/Board Member

26/04/2017

Gregory Gorgas

Corporate Officer/Principal

27/12/2016

Brandi Roberts

Director of Finance/CFO

31/10/2016

Robert Emanuele

Corporate Officer/Principal

30/04/2011

27/10/2016

Ioana C. Hone

Investor Relations Contact	-	-
Public Communications Contact	-	-

Mette Vinge

General Counsel

31/12/2018

Age distribution of managers

Parity Men Women

Male	15
Female	2

Of which Executive Committee

Male	6
Female	1

Of which Directors

Male	6
Female	0

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Companyâ€™s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Employees

Sector

Biotechnology & Medical Research

More about the company